ClinicalTrials.Veeva

Menu

IL-6, IL-12, IL-15 and IL-23 Expression Levels in Rheumatoid Arthritis Patients

A

Assiut University

Status

Not yet enrolling

Conditions

Rheumatoid Arthritis

Treatments

Other: blood sample

Study type

Observational

Funder types

Other

Identifiers

NCT06558305
Interleukins in RA patients

Details and patient eligibility

About

Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation and articular damage.

Continuous medical research has dramatically improved the outcomes for patients with RA. Traditional therapeutic approaches have relied on glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying antirheumatic drugs (DMARDs) such as methotrexate, sulfasalazine or leflunomide. Glucocorticoids and NSAIDs interfere with the inflammatory cascades while DMARDs impede both the inflammatory and the destructive processes of RA.

These drugs, although efficient, are not specifically directed against inflammatory cells or cytokines and are associated with significant toxicity. The development of biologic DMARDs (bDMARDs), has been an important step forward. Their ability to neutralize specific cytokines or target distinct immune cells filled a gap in existing treatment options for RA. [3]. However, some patients still have only partial or no response to bDMARDs. More recently, a group of drugs has been developed that inhibit the janus kinase (JAK) family of intracellular tyrosine kinases, which transmit cytokine- mediated signals via the JAK-signal transducer and activator of transcription (STAT) pathway [4]. Baricitinib, with a selectivity to inhibit JAK1 and 2, has been FDA approved for RA in 2018 [5].

Many cytokines such IL-6, IL-12, IL-15, IL-23, (GM-CSF) and (IFNs) are associated with the pathogenesis of RA. These cytokines transduce signals via the JAK-STAT pathway.

Enrollment

80 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age is at leasr18 years old,
  • established RA diagnosis according to 2010 the American College of Rheumatology/European League against Rheumatism classification criteria

Exclusion criteria

  • Associated autoimmune diseases,
  • connective tissue diseases,
  • chronic liver or kidney diseases or
  • genetic diseases

Trial design

80 participants in 3 patient groups

Patients on cDMARDS
Treatment:
Other: blood sample
Patients on janus kinase (JAK) inhibitors
Treatment:
Other: blood sample
Control
Treatment:
Other: blood sample

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems